Case Report
Copyright ©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Surg. Mar 27, 2025; 17(3): 100951
Published online Mar 27, 2025. doi: 10.4240/wjgs.v17.i3.100951
Lung metastasis following temporary discontinuation of lenvatinib and tislelizumab in hepatocellular carcinoma: A case report
Chen-Dong Wang, Run-Dong Liu, Ming-Jie Liu, Jia Song
Chen-Dong Wang, Jia Song, Hepatic Surgery Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, Hubei Province, China
Run-Dong Liu, Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, Hubei Province, China
Ming-Jie Liu, Department of Oncology, Liyuan Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430062, Hubei Province, China
Co-first authors: Chen-Dong Wang and Run-Dong Liu.
Author contributions: Wang CD and Liu RD performed the data analysis and wrote the manuscript; Liu MJ collected the patient's clinical findings; Song J contributed to supervising and revising the manuscript.
Informed consent statement: Written informed consent was obtained from the patient.
Conflict-of-interest statement: The authors declare no competing interests.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Jia Song, PhD, Doctor, Hepatic Surgery Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 1095 Jiefang Avenue, Wuhan 430022, Hubei Province, China. tjhsongjia@hust.edu.cn
Received: August 31, 2024
Revised: December 4, 2024
Accepted: January 10, 2025
Published online: March 27, 2025
Processing time: 177 Days and 5.1 Hours
Core Tip

Core Tip: In recent years, targeted therapies, immunotherapies with immune checkpoint inhibitors, and localized interventions have effectively managed advanced or non-resectable hepatocellular carcinoma (HCC). Despite these advances, few studies have addressed the crucial need for management strategies during the perioperative period for patients with HCC. To our knowledge, this is the first report to illuminate the potential risk of disease progression and lung metastasis after the temporary cessation of targeted therapy with lenvatinib and immunotherapy with tislelizumab. This finding reveals the importance of refining treatment protocols to reduce the risks of recurrence and metastasis.